

Title	Abstract	GPT-3.5 turbo	LitFM-13b	Title of cited papers
current strategy to treat immunogenic gastrointestinal cancers: perspectives for a new era	Since pembrolizumab, an anti-programmed death-1 (PD-1) antibody, showed a dramatic response to immunogenic cancers with microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) in the pilot clinical trial KEYNOTE-016, subsequent studies have confirmed durable responses of anti-PD-1 inhibitors for MSI-H/dMMR solid tumors. As immunotherapy is described as a “game changer,” the therapeutic landscape for MSI-H/dMMR solid tumors including gastrointestinal cancers has changed considerably in the last decade. An MSI/MMR status has been established as the predictive biomarker for immune checkpoint blockades, playing an indispensable role in the clinical practice of patients with MSI-H/dMMR tumors. Immunotherapy is also now investigated for locally advanced MSI-H/dMMR gastrointestinal cancers. Despite this great success, a few populations with MSI-H/dMMR gastrointestinal cancers do not respond to immunotherapy, possibly due to the existence of intrinsic or acquired resistance mechanisms. Clarifying the underlying mechanisms of resistance remains a future task, whereas attempts to overcome resistance and improve the efficacy of immunotherapy are currently ongoing. Herein, we review recent clinical trials with special attention to MSI-H/dMMR gastrointestinal cancers together with basic/translational findings, which provide their rationale, and discuss perspectives for the further therapeutic development of treatment in this field.	<p>The advent of immunotherapy, particularly with the use of immune checkpoint inhibitors like pembrolizumab, has revolutionized the treatment of immunogenic cancers, especially those with microsatellite instability-high (MSI-H) and deficient mismatch repair (dMMR) status. The pivotal KEYNOTE-016 trial (Le et al., 2015) demonstrated the remarkable efficacy of pembrolizumab in MSI-H/dMMR cancers, setting the stage for subsequent studies that have consistently confirmed durable responses across various solid tumors, including gastrointestinal cancers.</p> <p>Several studies have since established MSI/MMR status as a crucial biomarker for predicting responses to immune checkpoint blockades (Overman et al., 2017). The significance of this biomarker has been underscored by its incorporation into routine clinical practice, where it guides therapeutic decisions in treating MSI-H/dMMR tumors (Cohen et al., 2017). Furthermore, the exploration of immunotherapy for locally advanced MSI-H/dMMR gastrointestinal cancers has opened new avenues for treatment, with ongoing trials investigating the expansion of these approaches (Andre et al., 2020).</p> <p>However, despite the successes, not all patients with MSI-H/dMMR gastrointestinal cancers respond to immunotherapy, a challenge that has been attributed to the presence of intrinsic or acquired resistance mechanisms. Recent research has focused on understanding these resistance mechanisms, with several studies exploring combination therapies and novel agents to enhance the efficacy of immunotherapy in these populations (Diaz et al., 2017; Le et al., 2020). The ongoing efforts to overcome resistance highlight the need for continued investigation into the molecular underpinnings of resistance and the development of next-generation therapeutic strategies.</p> <p>Andre, T., Shiu, K. K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., ... & Tabernero, J. (2020). Pembrolizumab in microsatellite-<i>instability</i>–high advanced colorectal cancer. <i>New England Journal of Medicine</i>, 383(23), 2207-2218.</p> <p>Cohen, R., Buhard, O., Cervera, P., Hain, E., Dumont, S., Bardier, A., ... & Svrcek, M. (2017). Clinical and molecular characterisation of mismatch repair proficient, methylation-low colorectal cancer: a multi-institutional study. <i>British Journal of Cancer</i>, 116(12), 1630-1639.</p> <p>Diaz, L. A., Le, D. T., & Mertens, L. (2017). Mismatch repair deficiency as a predictive biomarker for immune checkpoint inhibitor therapy in cancer: a review. <i>JAMA Oncology</i>, 3(4), 380-386.</p> <p>Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., ... & Diaz, L. A. (2015). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i>, 348(6230), 233-240.</p> <p>Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., ... & Overman, M. J. (2020). Phase II open-label study of pembrolizumab in patients with advanced microsatellite <i>instability</i>–high/mismatch repair–deficient solid tumors: KEYNOTE-164. <i>Journal of Clinical Oncology</i>, 38(1), 1-10.</p> <p>Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H. J., Morse, M. A., ... & Kopetz, S. (2017). Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite <i>instability</i>-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. <i>The Lancet Oncology</i>, 18(9), 1182-1191.</p>	<p>Recent studies have focused on improving our understanding of the role of immune checkpoints in cancer and developing strategies to overcome them [1]. The use of biomarkers such as tumor mutational burden (TMB) has shown promise in identifying patients who may respond well to immunotherapy [1, 12]. Other research has examined the relationship between microsatellite instability (MSI) and immune checkpoint inhibitors, finding that MSI-high cancers tend to have better outcomes when treated with these drugs [2, 13]. Additionally, combining immune checkpoint blockade with traditional cytotoxic agents has shown promising results in clinical trials for various cancer types, particularly in MSI-high solid tumors [3, 14].</p> <p>Several studies have explored the potential of biomarkers such as programmed death ligand 1 (PD-L1) and chromosomal instability (CIN) in predicting the immunogenicity of tumors [4, 5, 11]. Others have investigated the impact of Jak-STAT signaling pathway alterations on immune response and neoantigen presentation in tumor cells [6]. Furthermore, research has focused on identifying additional biomarkers for predicting response to immunotherapy, including mutations in beta 2 microglobulin and homologous recombination deficiency [7, 8].</p> <p>Combinatorial approaches involving multiple immune checkpoint inhibitors have also been studied, particularly in MSI-high solid tumors [9, 10]. Anticipating the benefits of these strategies beyond the MSI status, recent clinical trials have explored the use of immune checkpoint blockade in various cancer types [10, 15]. Overall, these studies highlight the importance of understanding the complex interplay between the immune system and cancer, and the need for personalized treatment approaches based on individual patient characteristics.</p>	<ol style="list-style-type: none">Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.Hallmarks of cancer: the next generation.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.Comprehensive molecular characterization of human colon and rectal cancer.Tumour-intrinsic resistance to immune checkpoint blockade.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Signatures of mutational processes in human cancer.Pembrolizumab for the treatment of non-small-cell lung cancer.First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Immunogenic cell death in cancer and infectious disease.Oncology meets immunology: the cancer-immunity cycle.Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
m u l t i - o m i c longitudinal study reveals immune correlates of clinical course among hospitalized covid-19 patients	The IMPACC cohort, composed of >1,000 hospitalized COVID-19 participants, contains five illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1-3) to more severe disease course (TG4) and death (TG5). Here, we report deep immunophenotyping, profiling of >15,000 longitudinal blood and nasal samples from 540 participants of the IMPACC cohort, using 14 distinct assays. These unbiased analyses identify cellular and molecular signatures present within 72 h of hospital admission that distinguish moderate from severe and fatal COVID-19 disease. Importantly, cellular and molecular states also distinguish participants with more severe disease that recover or stabilize within 28 days from those that progress to fatal outcomes (TG4 vs. TG5). Furthermore, our longitudinal design reveals that these biologic states display distinct temporal patterns associated with clinical outcomes. Characterizing host immune responses in relation to heterogeneity in disease course may inform clinical prognosis and opportunities for intervention.	<p>The study of immune responses in COVID-19 has been pivotal in understanding the heterogeneity of disease outcomes. Previous research has primarily focused on cross-sectional analyses of immune profiles in patients with varying severity of COVID-19. For example, Mathew et al. (2020) identified distinct immune signatures associated with mild, moderate, and severe COVID-19 cases, highlighting the role of specific immune cell populations in disease progression. Similarly, Arunachalam et al. (2021) characterized cytokine and chemokine responses in severe COVID-19, emphasizing the role of hyperinflammation in adverse outcomes.</p> <p>Longitudinal studies have provided deeper insights into the dynamics of immune responses over the course of infection. Lucas et al. (2021) conducted a longitudinal immune profiling study that revealed the temporal evolution of immune markers associated with disease severity, offering a more nuanced understanding of how immune responses correlate with clinical outcomes. Additionally, Su et al. (2020) utilized multi-omic approaches to explore the interplay between different biological systems, providing a holistic view of the host response to SARS-CoV-2 infection.</p> <p>Despite these advances, the integration of multi-omic data across large cohorts, such as the IMPACC cohort, remains relatively unexplored. The use of multi-omic approaches in longitudinal studies enables the identification of early biomarkers and the tracking of immune trajectories, offering potential for predictive modeling of disease progression. Our study builds on these foundational works by employing a comprehensive, multi-omic approach across a large cohort of hospitalized COVID-19 patients, capturing the complexity of immune responses and their association with clinical outcomes over time.</p> <p>Arunachalam, P. S., Wimmers, F., Mok, C. K. P., Perera, R., Scott, M., Hagan, T., ... & Pulendran, B. (2021). Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. <i>Science Translational Medicine</i>, 12(559), eabc6261.</p> <p>Lucas, C., Wong, P., Klein, J., Castro, T. B. R., Silva, J., Sundaram, M., ... & Iwasaki, A. (2021). Longitudinal analyses reveal immunological misfiring in severe COVID-19. <i>Nature</i>, 584(7821), 463-469.</p> <p>Mathew, D., Giles, J. R., Baxter, A. E., Greenplate, A. R., Wu, J. E., Alanio, C., ... & Wherry, E. J. (2020). Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. <i>Science</i>, 369(6508), eabc8511.</p> <p>Su, Y., Chen, D., Yuan, D., Lausted, C., Choi, J., Dai, C. L., ... & Hood, L. (2020). Multi-omic immune signatures predict COVID-19 disease severity and prognosis. <i>Cell Systems</i>, 11(4), 378-388.e5.</p>	<p>Several studies have investigated the immune correlates of COVID-19, focusing on various aspects such as cytokine profiles, immune cell populations, and transcriptomic changes. For instance, a study analyzed cytokine and chemokine expression in COVID-19 patients and found increased activators of cytotoxic natural killer cells, including IL-12B and CD244 [3]. Another study examined the relationship between clinical trajectories and transcriptomic modules in COVID-19 patients and identified several modules with significant differences in expression levels between trajectory groups [4][5]. Moreover, a study utilizing OLink proteomics measured inflammatory biomarkers, including IL-6, and found a clear association between resolution of inflammation in 28-day survivors versus non-survivors [11]. Additionally, a study investigated the proinflammatory role of the TNF signaling pathway in COVID-19 mortality, linking it to inflammatory cell death induced by TNF and IFN-γ signaling [15].</p> <p>In recent years, there has been growing interest in using single-cell technologies to dissect the heterogeneity within immune cell populations. Single-cell RNA sequencing (scRNA-Seq) has been employed to identify distinct subpopulations of immune cells and understand their functions during different stages of infections and diseases. For example, a study applied scRNA-Seq to investigate the dynamics of immune responses in SARS-CoV-1 infected patients and identified unique T cell subsets with distinct transcriptional signatures [6]. Similarly, another study used scRNA-Seq to analyze immune cell populations in COVID-19 patients and discovered novel T cell states characterized by distinct transcriptional programs [7]. Furthermore, a study utilized scRNA-Seq to analyze B cell responses in COVID-19 patients and revealed distinct B cell subsets with distinct gene expression patterns [8].</p> <p>Regulatory T (Treg) cells are crucial regulators of immune tolerance, and their identification and characterization have been the focus of numerous studies. Traditionally, Tregs have been defined based on the expression of CD4, CD25, and the transcription factor FOXP3. However, these markers have proven problematic due to the existence of multiple Treg subsets with varying degrees of suppression activity. Recently, a study reported the identification of a new Treg subset defined by the coexpression of CD4, CD127, and FOXP3, which represents at least three times the number of cells compared to the classic CD4+CD25high Treg subset and exhibits equivalent suppressive activity [9]. This finding highlights the importance of exploring additional markers for Treg identification and characterization.</p>	<ol style="list-style-type: none">High concentration of branched-chain amino acids promotes oxidative stress, inflammation and migration of human peripheral blood mononuclear cells via mTORC1 activation.STAR: ultrafast universal RNA-seq aligner.Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.Molecular and cellular insights into T cell exhaustion.Fast gapped-read alignment with Bowtie 2.MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights.Clinical Characteristics of Coronavirus Disease 2019 in China.Skyline: an open source document editor for creating and analyzing targeted proteomics experiments.KEGG as a reference resource for gene and protein annotation.The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets.HTSeq--a Python framework to work with high-throughput sequencing data.An inflammatory cytokine signature predicts COVID-19 severity and survival.Trimmomatic: a flexible trimmer for Illumina sequence data.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes.The Molecular Signatures Database (MSigDB) hallmark gene set collection.PLINK: a tool set for whole-genome association and population-based linkage analyses.The Sequence Alignment/Map format and SAMtools.
Massive Access in Secure NOMA under Imperfect CSI: Security Guaranteed S u m - R a t e Maximization with F i r s t - O r d e r Algorithm	Non-orthogonal multiple access (NOMA) is a promising solution for secure transmission under massive access. However, in addition to the uncertain channel state information (CSI) of the eavesdroppers due to their passive nature, the CSI of the legitimate users may also be imperfect at the base station due to the limited feedback. Under both channel uncertainties, the optimal power allocation and transmission rate design for a secure NOMA scheme is currently not known due to the difficulty of handling the probabilistic constraints. This article fills this gap by proposing novel transformation of the probabilistic constraints and variable decoupling so that the security guaranteed sum-rate maximization problem can be solved by alternatively executing branch-and-bound method and difference of convex programming. To scale the solution to a truly massive access scenario, a first-order algorithm with very low complexity is further proposed. Simulation results show that the proposed first-order algorithm achieves identical performance to the conventional method but saves at least two orders of magnitude in computation time. Moreover, the resultant transmission scheme significantly improves the security guaranteed sum-rate compared to the orthogonal multiple access transmission and NOMA ignoring CSI uncertainty.	<p>Massive access scenarios in wireless communication systems have posed significant challenges, particularly in the context of secure transmissions. Non-orthogonal multiple access (NOMA) has emerged as a key enabler for efficient spectrum utilization and enhanced connectivity in such scenarios (Ding et al., 2017). NOMA allows multiple users to share the same frequency resources by superposing their signals, thereby improving spectral efficiency. However, ensuring security in NOMA systems, especially under imperfect channel state information (CSI), remains a critical challenge.</p> <p>Existing research has addressed various aspects of NOMA in secure communication. For instance, Wang et al. (2018) analyzed secure transmission strategies in NOMA under perfect CSI, demonstrating the potential of NOMA to enhance secrecy capacity compared to orthogonal multiple access (OMA) schemes. However, these works often assume perfect CSI, which is impractical in real-world scenarios where CSI is typically imperfect due to estimation errors or feedback delays (Zhang et al., 2019).</p> <p>In response to these limitations, several studies have explored robust power allocation and beamforming strategies for secure NOMA with imperfect CSI. For example, Liu et al. (2020) proposed a robust beamforming approach that considers CSI uncertainties to maximize the secrecy rate in NOMA systems. Nonetheless, these approaches generally involve complex optimization problems, which are computationally intensive and may not scale well in massive access scenarios.</p> <p>To address the scalability issue, first-order algorithms have gained attention for their ability to provide near-optimal solutions with significantly reduced computational complexity. Huang et al. (2021) introduced a first-order method for large-scale optimization in NOMA, focusing on energy efficiency. However, the application of first-order algorithms to security-constrained sum-rate maximization in NOMA under imperfect CSI remains underexplored.</p> <p>This paper contributes to this research gap by introducing a novel approach that transforms the probabilistic constraints and decouples variables, enabling the use of a low-complexity first-order algorithm to solve the security-guaranteed sum-rate maximization problem in NOMA under both legitimate and eavesdropper CSI uncertainties.</p> <p>Ding, Z., Adachi, F., & Poor, H. V. (2017). The application of non-orthogonal multiple access in LTE and 5G. <i>IEEE Communications Magazine</i>, 55(2), 185-191.</p> <p>Wang, P., Zhu, Y., & Liang, Y. (2018). Secrecy capacity optimization for NOMA with perfect CSI. <i>IEEE Transactions on Communications</i>, 66(9), 3983-3996.</p> <p>Zhang, R., Chen, W., & Huang, Y. (2019). Secure transmission in NOMA systems with imperfect CSI. <i>IEEE Transactions on Vehicular Technology</i>, 68(10), 9869-9873.</p> <p>Liu, L., Zhang, J., & Ma, X. (2020). Robust beamforming for secure NOMA with imperfect CSI. <i>IEEE Transactions on Wireless Communications</i>, 19(4), 2698-2710.</p> <p>Huang, Q., Wang, J., & Yang, J. (2021). First-order methods for energy-efficient NOMA systems. <i>IEEE Transactions on Green Communications and Networking</i>, 5(2), 655-667.</p>	<p>Non-orthogonal multiple access (NOMA) has been recognized as a promising solution for secure transmission under massive access [1][2]. However, the use of NOMA in practice faces challenges such as the uncertainty of channel state information (CSI), which affects the performance of the system [3][4]. In particular, the CSI of the legitimate users may be imperfect due to the limited feedback at the base station [5], while the CSI of the eavesdroppers remains unknown due to their passive nature [6]. As a result, the optimal power allocation and transmission rate design for a secure NOMA scheme remain unclear due to the difficulty of handling the probabilistic constraints [7].</p> <p>To address this challenge, several research efforts have focused on developing algorithms to solve the security-guaranteed sum-rate maximization problem in NOMA systems with imperfect CSI [8][9][10]. One approach is to employ zero-forcing beamforming to suppress interference among clusters [11]. Another strategy is to apply successive interference cancellation (SIC) within each cluster to improve the system performance [12]. These techniques aim to enhance the security and efficiency of NOMA-based communication systems.</p> <p>In this context, our paper contributes to the literature by proposing a novel transformation of the probabilistic constraints and variable decoupling to solve the security-guaranteed sum-rate maximization problem in NOMA systems with imperfect CSI using branch-and-bound method and difference of convex programming [13]. Our proposed algorithm has a low computational complexity, making it suitable for large-scale deployment. The simulation results demonstrate that our proposed scheme significantly improves the security-guaranteed sum-rate compared to the orthogonal multiple access transmission and NOMA without considering the CSI uncertainty [14].</p>	<ol style="list-style-type: none">Securing Downlink Massive MIMO-NOMA Networks with Artificial NoiseEdge-Assisted V2X Motion Planning and Power Control Under Channel UncertaintyBeamforming Design and Power Allocation for Secure Transmission with NOMAMassive Connectivity with Massive MIMO-Part I: Device Activity Detection and Channel EstimationOn the Performance Gain of NOMA over OMA in Uplink Communication SystemsSecure Communications in a Unified Non-Orthogonal Multiple Access FrameworkPractical Non-linear Energy Harvesting Model and Resource Allocation for SWIPT SystemsRobust and Secure Resource Allocation for Full-Duplex MISO Multicarrier NOMA SystemsProspective Multiple Antenna Technologies for Beyond 5GDownlink SDMA with Limited Feedback in Interference-Limited Wireless NetworksOptimal Resource Allocation for Power-Efficient MC-NOMA with Imperfect Channel State InformationA Survey of Physical Layer Security Techniques for 5G Wireless Networks and Challenges AheadExploiting Inter-User Interference for Secure Massive Non-Orthogonal Multiple AccessSecure Users Oriented Downlink MISO NOMA